Effect of magnesium therapy in non-ischemic ventricular tachycardia

Background/Aim: Ventricular tachycardia (VT) episodes in non-ischemic cardiomyopathy are a very challenging condition. We aimed to reduce implantable cardioverter defibrillator (ICD) shock in this group of patients with oral magnesium (Mg) therapy. Materials and methods: A total of 17 patients who underwent ICD implantation for non-ischemic cardiomyopathy and presented with frequent shocks were included in the study. In addition to standard treatment, Mg therapy was added to these patients and their ICD shock status was evaluated. Result: A significant decrease in the number of ICD shocks before and after treatment was detected, and statistical significance was observed (3.41 (1 - 7) vs. 0.47 (0 - 2) p = 0.001). The other important finding was a significant decrease in anti-tachycardia pace therapy, which was statistically significant (3.76 (1 - 15) vs. 2.71 (0 - 10) p = 0.013). In line with these two positive results, VT was found to decrease. Conclusion: Oral Mg treatment in patients with nonischemic cardiomyopathy who underwent ICD shock due to VT episodes reduced VT episodes in addition to standard treatment.